(Lung Cancer) Nivolumab + Bevacizumab + Chemotherapy as a New Treatment
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- June 30, 2021
- Read time: 1 minute
On June 21, 2021, Ono Pharmaceutical Industry Co., Ltd. announced modifications to the Opdivo (nivolumab) package insert, adding nivolumab + bevacizumab + chemotherapy as a new treatment option for patients with unresectable or recurrent non-small cell lung cancer.
This modification was based on the results of the TASUKI-52 Phase 3 clinical trial, a multicenter, double-blind, randomized Phase 3 trial dividing chemotherapy-naive, unresectable or recurrent non-squamous non-small cell lung cancer patients unsuitable for radiotherapy into two groups: nivolumab + bevacizumab + chemotherapy versus placebo + bevacizumab + chemotherapy. Interim analysis results showed that compared with the placebo group, the nivolumab group demonstrated extended progression-free survival as the primary endpoint.
Source: https://www.ono.co.jp/news/20210621.html
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4